- OUR MISSION
Better Life through Better Medicine
Contributing to improved quality of life and
public welfare by developing quality medicines
A company that has achieved numerous
‘firsts,’ ‘bests’ and ‘very bests’
Dedicated to pharmaceuticals since its foundation,
Chong Kun Dang has overcome many challenges,
while continuing to grow and contribute to the
advancement of Korea’s pharmaceutical industry.
In the days when Korea imported 100% of the raw
materials required for medicines from abroad,
we built Korea’s largest plants for chemical
synthesis and fermentation, making it possible to
produce pharmaceutical ingredients locally using
our own technology. From there, we had driven
Korean Pharmaceutical Industry with this
breakthrough on the path toward modernization.
Furthermore, we became the first Korean pharmaceutical company to export products to the US
market through the obtainment of the U.S. FDA approval.
Now, on its 75th anniversary, we promise to put all efforts to lead continuous change and innovation,
positioning Chong Kun Dang as a global pharmaceutical company with a competitive edge in the
CHONG KUN DANG about President Young-Joo Kim Foundation May 7, 1941 (Spin off on : November 5, 2013) Business Line Manufacturing, Sales and Marketing of Medicine Paid in Capital 23,5 Bil. (Won) Head Office 8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea TEL/FAX 82-2-2194-0300 / 82-2-2194-0369 Homepage www.ckdpharm.com
Chong Kun Dang Pharmaceutical Corp. is one of leading Korean pharmaceutical manufacturers and has a great
strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia
and anti-diabetics but also with OTC drugs such as Penzal, Prefemine, Modcol and consumer health such as
insecticides, hairdye, etc.
- Chong Kun Dang has a complete portfolio of prescription
pharmaceutical products for the entire segment and therapeutic
classes, supported not only by own-developed NCE drugs
Camptobell as a anticancer and anti-diabetic, Duvie, but also
anti-hypertension Dilatrend, Telminuvo, anti-hyperlipidemia Lipilou,
and immunosuppressant Tacrbell.
- Over-the-counter (OTC)
- Chong Kun Dang’s OTC drugs consist of products known for their
therapeutic benefits, as well as supplements and other preventive
products. Penzal which is best-seller for headache in Korea,
Zelcom as No.1 antithelmintic, and fast-effective digestive Sok-
chung drink carry strong brand names that have dominated the
market over the past few decades. In recent days, some of Chong
Kun Dang’s preventive OTCs are positioning to advance women’s
health such as Prefemine for premenstrual syndrome and
Simidona for menopause symptom, Bolgre for iron supplements.
- Health Supplements
- Chong Kun Dang provides high-quality healthcare supplements
with preventive benefits including prebiotics complex Prelacto and
Premium Omega-3+vitamin series caring for modern people in their
Global business presence
Chong Kun Dang is expanding the market in worldwide with strategic products in immunosuppressants,
anti-cancers and antibiotics. In order to grow strength in Glocalization (Globalization + Localization),
Chong Kun Dang opened representative office in Vietnam since 2012 and established Joint Venture company
in Indonesia in 2015.
Chong Kun Dang’s manufacturing site in CheonAn city supply quality
prescribed products meeting with global standard into worldwide as Japan,
China, South-east Asian, MENA and African countries.
In recent, it is being strengthen to dominant market share in ASEAN region
through Indonesian JV company, VN rep. office and further footholds.
In September 2015, Chong Kun Dang has established the joint venture
company PT CKD OTTO Pharmaceuticals with PT OTTO Pharmaceutical Ltd.
which is one of leading local pharmaceutical companies in Indonesia. In the
future, PT CKD OTTO as a production base not only for domestic market, but
only for near Asian, MENA and EU countries, will manufacture and distribute
anti-cancer drugs such as Belloxa, Gemtan, etc. through which Chong Kun
Dang has global competitiveness.
Vietnam Rep. Office
Since Chong Kun Dang’s Vietnam representative office has been established
in 2012, it has been raised company awareness in domestic by expanding
the pipeline of prescription drugs as well as health care products.
Through various promotion activity, oncology products (Belloxa, Gemtan),
anti-hypertensives (Candemore plus), antibiotics (Kmoxilin) and various
health care products including red-ginseng liquid, collagen capsule,
probiotics, etc are being distributed in nationwide.
Licensing and Tech Transfer
Chong Kun Dang is focused on in-licensing novel drugs which offers better solution for chronic disorders such as
diabetes and cardiovascular diseases, as well as for anti-cancer therapies and neurological diseases with high
medical unmet needs. Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively
expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 and CKD-581) and dyslipidemia
therapy (CKD-519), starting from the neighboring Asian markets. Further, Chong Kun Dang has an in-house
technology platform for HDAC6-selective inhibitors which provides the novel mechanism of action.
We are enthusiastically preparing for the global market entry via strategic business diversification, specifically
targeting auto-immune diseases, neurological disorders, and cancer.
Supported by its long presence in Korean pharmaceutical industry and strong sales and marketing capacity,
Chong Kun Dang is involved in numerous business alliance relationships with the most prestigious multinational
companies in various fields.
Over the last decade, Chong Kun Dang has formed the partnership with MNCs such as Bayer, Roche, Allergan, Pfizer,
and MSD and, as a result, Chong Kun Dang has an unrivaled leadership in the local market enhanced by its robust
product portfolio which now covers a broad range of therapeutic classes with innovative, outstanding drugs.
Chong Kun Dang will continue to work towards mutual development through global business partnering.독일스위스미국일본프랑스이탈리아코스타리카캐나다
사업제휴 국가 Country Affiliated Companies Product Names GERMANY Bayer
Avelox®, Ciprobay®, Ciprouro®
Hospital Solns, Nutriflex®, Lipidem®
Dilatrend®, Tamiflu®, Kytril®, etc
Januvia® Family, Vytorin®, Atozet®
JAPAN Mitsubishi Tanabe
COSTA RICA Newport PrinosineⓇ CANADA Valeant
Cheon-An plant located in Cheon-An City, ChungCheongNam Do with area of
13,700㎡ and gross floor area of 5,000㎡ is a high-tech manufacturing site
where the process of dispensing raw materials, production, packaging and
release of finished products is controlled by automated warehousing
Cheon-An plant established aspects of global pharmaceutical production facility through completion
of separated cephalosporin and penicillin plants with level of cGMP in 2013, and certified the GMP
(Good manufacturing practice) compliance through inspections of several domestic and foreign
regulatory authorities. Also, the plant has maximized the operating efficiency successively starting
with establishment of SAP ERP (Enterprise Resource Planning) in 2010, QMS (Quality Management
System) and LIMS (Laboratory Information System) for efficient substantial manufacturing control
and quality assurance.
Cheon-An plant with high-tech production facility, excellent manufacturing and testing equipment and
optimized manufacturing environment is steadily evolving today through continued securing of human
resources and facility investment, and plays a pivotal role as a production base to realize value and
vision of global Chong Kun Dang Pharmaceutical Corp.
The warehouse establishes unmanned transport system for entire
logistical flows such as material dispensing, manufacturing, packaging
and warehousing of finished products by using LGV and RGV,
and supplies the medicinal product to hospitals, pharmacies, general
practitioners and so on through digital picking system.
Quality control team determines conformity of raw materials,
packaging materials and finished products to established
specifications after testing, and controls the quality so that customer
take safe medicinal products.
The laboratory conducts accurate test and contributes to GMP
compliance and development based on quality talent and advanced
Manufacture of over the counter and prescription drug
The process from materials to manufacture finished product is
controlled in compliance with GMP through advanced automation
equipment and verified process control.
Hyo-Jong Research Institute
Hyo : 曉 (Dawn), Jong : 鐘 (Bell)
Opening a new era by ringing the bell
Since the foundation, Chong Kun Dang has been
pursuing a disease-free society by developing
Cognizant of the importance of drug discovery,
Chong Kun Dang was the first in Korea to run its
own research institute; it also invested a huge
portion of its resources in nurturing and training
Chong Kun Dang Research Institute is
characterized by three independent laboratories:
The New Drug Discovery Labs, for identifying
innovative drug candidates,
The Technology Development Labs, dedicated to
generic drugs, APIs, and botanical drugs,
and the Bio Research Labs for developing
antibodies, vaccines, and recombinant proteins.
Chong Kun Dang was able to stand as one of the top local pharmaceutical companies with
distinguished achievements in drug development including the following :
·Two new drugs, Duvie (type II diabetes) and Camtobell (cancer), were developed successfully.·CKD-732 (Beloranib), which was developed by Chong Kun Dang and licensed out to an US-based
specialty pharma Zafgen, is now in development for Prader-Willi syndrome (P III) and severe obesity
(P II) in the US and EU.·CKD-11101, a biosimilar product to treat anemia is successfully in phase III clinical trial.
Chong Kun Dang strives to develop innovative new drugs by investing a significant amount of R&D
expenditure, spending 13.3% of net sales in 2014.
In order to accomplish our vision, Chong Kun Dang continuously increases R&D investment with 21%
of annual growth of since 2009.
R&D Vision & Strategy